Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals.
Aged
Alzheimer Disease
/ diagnostic imaging
Amyloid
/ metabolism
Amyloid beta-Peptides
/ metabolism
Amyloidogenic Proteins
/ metabolism
Amyloidosis
Apolipoprotein E4
/ genetics
Biomarkers
Cholinergic Agents
Diffusion Tensor Imaging
Female
Humans
Male
White Matter
/ pathology
tau Proteins
/ metabolism
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
11 10 2022
11 10 2022
Historique:
received:
28
10
2021
accepted:
19
05
2022
pubmed:
3
8
2022
medline:
13
10
2022
entrez:
2
8
2022
Statut:
ppublish
Résumé
Several pathologic processes might contribute to the degeneration of the cholinergic system in aging. We aimed to determine the contribution of amyloid, tau, and cerebrovascular biomarkers toward the degeneration of cholinergic white matter (WM) projections in cognitively unimpaired individuals. The contribution of amyloid and tau pathology was assessed through CSF levels of the Aβ We included 203 cognitively unimpaired individuals from the H70 Gothenburg Birth Cohort Studies (all individuals aged 70 years, 51% female). WM lesion burden was the most important contributor to the degeneration of both cholinergic pathways (increase in mean square error [IncMSE] = 98.8% in the external capsule pathway and IncMSE = 93.3% in the cingulum pathway). Levels of Aβ In cognitively unimpaired older individuals, WMLs play a central role in the degeneration of cholinergic pathways. Our findings highlight the importance of WM lesion burden in the elderly population, which should be considered in the development of prevention programs for neurodegeneration and cognitive impairment.
Sections du résumé
BACKGROUND AND OBJECTIVES
Several pathologic processes might contribute to the degeneration of the cholinergic system in aging. We aimed to determine the contribution of amyloid, tau, and cerebrovascular biomarkers toward the degeneration of cholinergic white matter (WM) projections in cognitively unimpaired individuals.
METHODS
The contribution of amyloid and tau pathology was assessed through CSF levels of the Aβ
RESULTS
We included 203 cognitively unimpaired individuals from the H70 Gothenburg Birth Cohort Studies (all individuals aged 70 years, 51% female). WM lesion burden was the most important contributor to the degeneration of both cholinergic pathways (increase in mean square error [IncMSE] = 98.8% in the external capsule pathway and IncMSE = 93.3% in the cingulum pathway). Levels of Aβ
DISCUSSION
In cognitively unimpaired older individuals, WMLs play a central role in the degeneration of cholinergic pathways. Our findings highlight the importance of WM lesion burden in the elderly population, which should be considered in the development of prevention programs for neurodegeneration and cognitive impairment.
Identifiants
pubmed: 35918153
pii: WNL.0000000000200930
doi: 10.1212/WNL.0000000000200930
pmc: PMC9559946
doi:
Substances chimiques
Amyloid
0
Amyloid beta-Peptides
0
Amyloidogenic Proteins
0
Apolipoprotein E4
0
Biomarkers
0
Cholinergic Agents
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1619-e1629Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neurology. 2009 Apr 21;72(16):1411-6
pubmed: 19380700
Neuroimage. 2012 Feb 15;59(4):3774-83
pubmed: 22119648
Dement Geriatr Cogn Disord. 2011;31(1):37-44
pubmed: 21135556
Neuroimage. 2007 Aug 15;37(2):530-8
pubmed: 17604650
Acta Neuropathol Commun. 2015 Sep 30;3:60
pubmed: 26419828
J Comp Neurol. 2013 Dec 15;521(18):4124-44
pubmed: 23852922
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
J Alzheimers Dis. 2017;60(1):201-210
pubmed: 28826189
Front Neuroinform. 2014 Jan 06;7:49
pubmed: 24432000
Front Aging Neurosci. 2014 Oct 07;6:264
pubmed: 25339897
Alzheimers Res Ther. 2019 Apr 22;11(1):34
pubmed: 31010420
Neurobiol Aging. 2013 Apr;34(4):1145-7
pubmed: 23036586
Neurology. 2022 Mar 1;98(9):e958-e967
pubmed: 34937781
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Neurobiol Aging. 2018 Dec;72:171-176
pubmed: 30292090
Neurobiol Aging. 2021 May;101:1-12
pubmed: 33548794
J Alzheimers Dis. 2017;60(3):977-987
pubmed: 28984600
Hum Brain Mapp. 2019 Feb 15;40(3):868-878
pubmed: 30311315
Neuroimage. 2010 Feb 1;49(3):2457-66
pubmed: 19818860
Aging (Albany NY). 2021 Aug 25;13(16):19963-19977
pubmed: 34433132
Neuropsychologia. 2003;41(8):919-31
pubmed: 12667528
J Alzheimers Dis. 2014;39(4):871-81
pubmed: 24305500
Front Aging Neurosci. 2022 Jan 12;13:777475
pubmed: 35095467
J Aging Res. 2013;2013:198471
pubmed: 23401776
J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):9-14
pubmed: 11118240
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):160-4
pubmed: 21047883
Eur J Epidemiol. 2019 Feb;34(2):191-209
pubmed: 30421322
Stroke. 2015 Sep;46(9):2661-4
pubmed: 26173729
J Geriatr Psychiatry Neurol. 2012 Jun;25(2):122-7
pubmed: 22689705
Neuroimage. 2020 May 1;211:116607
pubmed: 32035186
Alzheimers Res Ther. 2019 Oct 10;11(1):83
pubmed: 31601267
Neurobiol Aging. 2018 Aug;68:48-58
pubmed: 29704648
Neurology. 2021 Oct 19;97(16):e1608-e1619
pubmed: 34521692
Med Image Anal. 2008 Feb;12(1):26-41
pubmed: 17659998
Arch Neurol. 2007 Feb;64(2):266-72
pubmed: 17296844
Neuroimage Clin. 2020;28:102495
pubmed: 33395986
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Behav Brain Res. 2011 Aug 10;221(2):334-40
pubmed: 20060018
J Neurochem. 2002 May;81(3):481-96
pubmed: 12065657
Aging (Albany NY). 2020 Jan 12;12(1):894-901
pubmed: 31927535
Hum Brain Mapp. 2011 Sep;32(9):1349-62
pubmed: 20672311